Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model

Monoclonal antibodies (mAbs) have been a spectacular clinical and commercial success in the treatment of cancer and autoimmune diseases. Many of these mAbs (for example, OKT3, Campath-1H, rituximab and infliximab) are against surface or secreted products of lymphocytes. However, mAbs can have a vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Brady, Jamie L, Harrison, Leonard C, Goodman, David J, Cowan, Peter J, Hawthorne, Wayne J, O'Connell, Philip J, Sutherland, Robyn M, Lew, Andrew M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282178/
https://www.ncbi.nlm.nih.gov/pubmed/25587392
http://dx.doi.org/10.1038/cti.2014.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282178/
https://www.ncbi.nlm.nih.gov/pubmed/25587392
http://dx.doi.org/10.1038/cti.2014.28

Ejemplares similares